What is the clinical evidence from this study?

Study design: Other. Population: Obesity. Intervention: IBIO-600 vs. Semaglutide alone or vehicle (mice); no concurrent control (monkeys). Primary outcome: Mean lean mass change from baseline at 12 weeks in cynomolgus monkeys.

What does this research mean for the field?

IBIO-600, a novel extended half-life monoclonal antibody that dually neutralizes myostatin and GDF11, preserves lean mass during GLP-1RA-mediated weight loss and produces sustained improvements in body composition in preclinical models. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to evaluate the efficacy of IBIO-600, a monoclonal antibody, in inhibiting myostatin and GDF11 to preserve skeletal muscle during weight loss.

July 3, 2026Open Access

Preclinical development of an extended half-life anti-myostatin monoclonal antibody

Key Result

A single administration of IBIO-600 in aged, obese cynomolgus monkeys demonstrated an elimination half-life of 52.4 days and increased lean mass by 8.22% at 12 weeks.

Key Points

This research aims to evaluate the efficacy of IBIO-600, a monoclonal antibody, in inhibiting myostatin and GDF11 to preserve skeletal muscle during weight loss.
Developed IBIO-600 for dual neutralization of myostatin and GDF11.
Evaluated IBIO-600 activity in cellular and preclinical models including diet-induced obese mice and aged cynomolgus monkeys.
Monitored muscle preservation and body composition effects after treatment with IBIO-600.
IBIO-600 reversed ligand-mediated suppression of myoblast differentiation in human skeletal myoblasts.
In diet-induced obese mice, IBIO-600 preserved lean mass relative to GLP-1RA monotherapy.
Single administration in aged monkeys resulted in a half-life of approximately 52 days, leading to sustained body composition improvements.

Structured PICO

Population

Preclinical study evaluating IBIO-600 in cellular models, diet-induced obese mice, and aged obese male cynomolgus monkeys followed for up to 12 weeks.

Intervention

IBIO-600 (extended half-life anti-myostatin/GDF11 monoclonal antibody). In mice: 1, 3, or 10 mg/kg + semaglutide for 4 weeks. In monkeys: single 5 mg/kg IV dose.

Comparator

In mice: vehicle + semaglutide only. In monkeys: baseline (no concurrent control group).

Outcome

Lean mass changes (assessed by DEXA), pSmad2 signaling neutralization, and pharmacokinetics (serum half-life).surrogate

IBIO-600, a dual myostatin and GDF11 inhibitor with an extended half-life, shows potential in preclinical models to preserve lean mass during GLP-1RA-mediated weight loss.

Limitations

Relatively short treatment duration may not fully capture longer-term effects on body composition.
Study was not designed to directly assess functional outcomes associated with changes in lean mass, such as muscle strength.
Group size used for cynomolgus monkeys (n = 3) was underpowered for analysis of body composition data.
Absence of a concurrent control group in the monkey study limits attribution of the observed body composition changes to treatment alone.

Abstract

Myostatin and growth differentiation factor 11 (GDF11) are closely related members of the transforming growth factor-β superfamily (TGF-β) that negatively regulate skeletal muscle growth. Pharmacologic inhibition of myostatin has been shown to preserve lean mass during glucagon-like peptide-1 receptor agonist (GLP-1RA) -mediated weight loss in persons with obesity. We developed IBIO-600, a long-acting monoclonal antibody which was engineered for dual neutralization of myostatin and GDF11. We evaluated IBIO-600 activity across cellular and preclinical models. Our evaluation of IBIO-600 demonstrated it reverses ligand-mediated suppression of myoblast differentiation in primary human skeletal myoblasts. In mechanistic in vitro studies, we further observed that GDF11 more potently modulates human myocyte and adipocyte biology than myostatin. In diet-induced obese mice treated with GLP-1RA, IBIO-600 preserves lean mass relative to GLP-1RA monotherapy. In aged, obese cynomolgus monkeys, a single administration of IBIO-600 demonstrates an elimination half-life of approximately 52 days and produces sustained improvements in body composition. These findings support further development of IBIO-600 as a differentiated approach to enhance muscle preservation and improve the quality of weight loss achieved with GLP-1RA-based therapies.

Ask AI

Helpful

Bookmark

View Full Paper